Rolling, Thierry http://orcid.org/0000-0002-0277-5067
Zhai, Bing http://orcid.org/0000-0001-6571-7465
Gjonbalaj, Mergim
Tosini, Nicholas http://orcid.org/0000-0001-7200-2695
Yasuma-Mitobe, Keiko
Fontana, Emily
Amoretti, Luigi A.
Wright, Roberta J.
Ponce, Doris M.
Perales, Miguel A. http://orcid.org/0000-0002-5910-4571
Xavier, Joao B. http://orcid.org/0000-0003-3592-1689
van den Brink, Marcel R. M. http://orcid.org/0000-0003-0696-4401
Markey, Kate A. http://orcid.org/0000-0002-7064-2362
Peled, Jonathan U. http://orcid.org/0000-0002-4029-7625
Taur, Ying http://orcid.org/0000-0002-6601-8284
Hohl, Tobias M. http://orcid.org/0000-0002-9097-5412
Funding for this research was provided by:
U.S. Department of Health & Human Services | National Institutes of Health (R01 AI093808, P30 CA008748, R21 AI105617, R21 AI156157, U01 AI124275, R01 CA228358, K08 HL143189, R01 AI137269)
Investigator in the Pathogenesis of Infectious Diseases Award from the Burroughs Wellcome Fund, the Ludwig Center for Cancer Immunotherapy, the Susan and Peter Solomon Divisional Genomics Program
Deutsche Forschungsgemeinschaft (RO-5328/2)
Takeda Science Foundation Fellowship
Article History
Received: 7 July 2021
Accepted: 22 September 2021
First Online: 11 November 2021
Change Date: 30 March 2022
Change Type: Update
Change Details: In the version of the Supplementary Data initially published in this article, decimals were missing in the second column of the “qpcr_results” tab, and have now been restored.
Competing interests
: J.U.P. reports research funding, intellectual property fees and travel reimbursement from Seres Therapeutics and consulting fees from DaVolterra, CSL Behring and from Maat Pharma. He has filed intellectual property applications related to the microbiome (reference nos. 62/843,849, 62/977,908 and 15/756,845). M.R.M.v.d.B. has received research support from Seres Therapeutics; he has consulted, received honorarium from or participated in advisory boards for Seres Therapeutics, WindMIL Therapeutics, Rheos, Frazier Healthcare Partners, Nektar Therapeutics, Notch Therapeutics, Forty Seven Inc., Priothera, Ceramedix, Lygenesis, Pluto Immunotherapeutics, Magenta Therapeutics, Merck & Co., Inc. and DKMS Medical Council (Board); and he has IP Licensing with Seres Therapeutics, Juno Therapeutics and stock options from Seres and Notch Therapeutics. T.M.H. has participated in a scientific advisory board for Boehringer-Ingelheim Inc.